GlassScriptPhysician profile
Andrew M Garcia
NPI 1073806212
$1,521.91
in general payments reported to CMS, 2019-2025
14 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2021: $36.66 · 2023: $39.45 · 2024: $640 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $274.45 | 2024-2025 | Rocklatan, Rhopressa, Clareon |
| Glaukos Corporation | $221.21 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Janssen Pharmaceuticals, INC | $216.02 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $156.88 | 2024 | Xdemvy |
| Rxsight INC | $146.70 | 2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Dompe US, INC. | $137.45 | 2025 | Oxervate |
| Harrow Eye, LLC | $126.55 | 2024-2025 | Vevye |
| Abbvie INC. | $69.88 | 2025 | |
| Genentech USA, INC. | $47.18 | 2024 | Vabysmo |
| Janssen Biotech, INC. | $36.66 | 2021 | |
| Apellis Pharmaceuticals, INC. | $31.96 | 2024 | Syfovre |
| Oyster Point Pharma, INC. | $22.06 | 2023 | Tyrvaya |
| Omeros Corporation | $17.52 | 2019 | |
| Horizon Therapeutics Plc | $17.39 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.